2023
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer
Fernandez-Martinez A, Pascual T, Singh B, Nuciforo P, Rashid N, Ballman K, Campbell J, Hoadley K, Spears P, Pare L, Brasó-Maristany F, Chic N, Krop I, Partridge A, Cortés J, Llombart-Cussac A, Prat A, Perou C, Carey L. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer. JAMA Oncology 2023, 9: 490-499. PMID: 36602784, PMCID: PMC9857319, DOI: 10.1001/jamaoncol.2022.6288.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsFemaleGene Expression ProfilingHumansImmunoglobulin GLapatinibLymphocytes, Tumor-InfiltratingMiddle AgedNeoadjuvant TherapyPaclitaxelPrognosisRandomized Controlled Trials as TopicReceptor, ErbB-2TranscriptomeTrastuzumabTreatment OutcomeConceptsEvent-free survivalHER2-positive breast cancerPathologic complete responseERBB2/HER2-positive breast cancerPrimary end pointGene expression signaturesBreast cancerEnd pointImmune signaturesPretreatment tumorPrognostic valueExpression signaturesHigher pathologic complete responseMultivariable Cox modelSecondary end pointsAdditive prognostic valueTumor-Infiltrating LymphocytesIntrinsic tumor subtypesWeekly paclitaxelNeoadjuvant treatmentClinicopathologic factorsComplete responseCox analysisMedian ageImmune activation
2019
Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.
Krop I, Paulson J, Campbell C, Kiermaier A, Andre F, Fumagalli D, de Haas S, Salgado R, Denkert C, Loibl S, Bailey A, Lewis Phillips G, Frank E, Piccart M, Viale G, Loi S. Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. Journal Of Clinical Oncology 2019, 37: 1012-1012. DOI: 10.1200/jco.2019.37.15_suppl.1012.Peer-Reviewed Original ResearchTumor-Infiltrating LymphocytesBreast cancerBetter prognosisComprehensive biomarker analysisPhase III studyInteraction p valueCase-control designBiomarker analysisHigher mRNA expressionAnthracycline useAPHINITY trialAdjuvant trastuzumabChemotherapy typeIII studyImmune signaturesNodal statusImmune markersInfiltrating lymphocytesClinical parametersPoor prognosisPredictive biomarkersTIL analysisBetter outcomesPAM50 subtypesPrognosis